Umbilical cord blood (UCB) has been increasingly used as an alternative stem cell source for patients without suitable HLAmatched related or unrelated donors. An estimated 730 000 UCB units have been donated and stored to date, and more than 35 000 UCB transplantations (UCBTs) have been performed worldwide. 1 Transient abnormal myelopoiesis (TAM) is a unique disorder that presents from fetal life to the first few days after birth and occurs in~10% of Down syndrome (DS) neonates.
2,3 TAM presents with clinical and morphological findings indistinguishable from acute megakaryoblastic leukemia (AMKL), but resolves spontaneously at a high rate within a few weeks or months of birth. 4 By contrast, myeloid leukemia associated with DS (ML-DS) as non-transient AMKL develops about 1-5 years later in~20% of these neonates. 5 TAM develops in the presence of constitutive trisomy 21 and a single GATA1 mutation. 6 Subsequent ML-DS evolves from a pre-existing TAM clone through the acquisition of additional gene mutations in cohesin or epigenetic regulators and in RAS or signal-transducing molecules. 6, 7 TAM uncommonly occurs in phenotypically normal neonates with trisomy 21 mosaicism 8, 9 or without trisomy 21. 10, 11 In this report, we describe a patient who developed TAM derived from donor cells about 4 months after UCBT for refractory angioimmunoblastic T-cell lymphoma (AITL). To our knowledge, this is the first report of donor cell-derived TAM (DCD TAM) as a specific complication of UCBT, which cannot occur after allogeneic stem cell transplantation using bone marrow (BM) or peripheral blood (PB).
This case report is a retrospective analysis of clinical and laboratory data. The study was approved by the Institutional Review Board of the Institute of Biomedical Research and Innovation and Kobe City Medical Center General Hospital, and informed consent was obtained from the patient, according to the Declaration of Helsinki.
A 62-year-old female who had a 3-year history of refractory AITL underwent UCBT from a one-Ag-mismatched unrelated male donor. The preparative regimen comprised fludarabine (180 mg/ m 2 ), melphalan (80 mg/m 2 ) and 4 Gy of TBI. GvHD prophylaxis consisted of tacrolimus and mycophenolate mofetil. The total nucleated cell dose was 3.1 × 10 7 /kg, including 0.9 × 10 5 /kg of CD34-positive cells. Neutrophil engraftment occurred on day +13 after UCBT following the administration of granulocyte-CSF. On day +30, BM analysis showed hypocellular marrow with trilineage hematopoiesis without any abnormal BM findings, and cytogenetic analysis of BM using G-banded chromosomes revealed a normal male karyotype of 46, XY. Chimerism analysis of PB mononuclear cells using STRs 12 revealed complete donor chimerism. On day +38, she was diagnosed with hepatic veno-occlusive disease and needed intensive care. On day +48, she developed transplant-associated thrombotic microangiopathy, and tacrolimus was tapered. Both complications gradually improved. On day +72, she had grade II acute GvHD of the skin, which was successfully treated with prednisolone. On day +119, a complete blood count revealed a white blood cell count of 43 × 10 8 /L with 8.0% blast cells, a hemoglobin concentration of 100 g/L and a platelet count of 20 × 10 9 /L. BM analysis showed hypocellular marrow with 9.5% blasts, which were medium-to-large sized with fine chromatin, prominent nucleoli and moderate amounts of basophilic cytoplasm with occasional cytoplasmic blebs ( Figure 1a ). The blasts were negative for myeloperoxidase and nonspecific esterase staining, and positive for CD34, CD117, CD33, CD7, CD4, CD36 and CD41 in immunophenotypic analysis. Cytogenetic analysis of BM without phytohemagglutinin showed the karyotype 47, XY, +21 [10] /46, XY [10] (Figure 1b) . However, chimerism analysis of PB showed complete donor chimerism. Blasts in PB spontaneously disappeared within 1 week after the onset of leukemia without administration of chemotherapy. On day +146, blasts in BM could not be detected by flow cytometric analysis using the blast-specific Ag. Cytogenetic analysis of BM revealed a normal male karyotype. Complete donor chimerism was maintained in PB. Because of the spontaneous remission of leukemia with morphological features of AMKL following UCBT and the presence of trisomy 21, we suspected the leukemia was DCD TAM. To confirm this diagnosis, we retrospectively analyzed samples of cord blood (CB) and BM after UCBT.
FISH analysis for trisomy 21 was performed for mononuclear cells of BM on day +30, +119 and +146 after UCBT, but not for CB because it was not viable. A three-signal pattern for chromosome 21 was detected only in a sample on day +119, with a frequency of 13% (Figure 1c) , and the others were negative. The falsepositive rate of the test was o 2.9%. Deep sequencing of GATA1 using amplified DNA extracted from CB and BM on day +30, +119 and +146 after UCBT was performed according to a previous report. 6 A GATA1 mutation (c.C189A, p.Y63X) with a mutation load of 9.0% (variant allele frequency (VAF) 0.09 (123/1353 reads)) was identified only in one sample on day +119 (Figure 1d) , and the others were negative (VAF o0.001; 0.0005 (4/8141 reads) in the PB of a negative control; 0.0001 (1/6704 reads) in the CB; 0.0002 (3/10375 reads) on day +30; and 0.0003 (4/12874 reads) on day +146). Taken together, trisomy 21 and a GATA1 mutation were detected only at the onset of DCD TAM. Targeted sequencing of 56 genes implicated in myeloid leukemogenesis, including somatic mutations accumulated during progression from TAM to DS-ML (Supplementary Table S1) 6,7 was also performed as described previously, 6 using a sample on day +119. Excluding the GATA1 mutation, we identified no other mutations. (The mean depth-of-targeted sequencing was 792 × . The threshold of VAF used to detect somatic mutations was 0.02.) The patient is now free from both AITL and DCD TAM 24 months after UCBT. Her clinical course after UCBT is shown in Figure 2 .
This case highlights that DCD TAM can develop as a specific complication of UCBT because TAM develops when fetal liver hematopoietic stem and progenitor cells (HSPCs), which are also involved in CB, acquire both constitutive trisomy 21 and a GATA1 mutation. 5, 13 In addition, TAM derived from fetal liver HSPCs is the most logical explanation for the spontaneous remission within the first few months of life because the major site of hematopoiesis switches from the fetal liver before birth to BM after birth. 5 TAM can occur not only in DS neonates but also uncommonly in phenotypically normal neonates, who have either mosaic for trisomy 21 8, 9 or an acquired trisomy 21 restricted to the leukemic clone. 10, 11 Retrospective analysis of neonatal blood spots in DS neonates with TAM demonstrated that a GATA1 mutation was already present at birth.
14 In our case, trisomy 21 and a GATA1 mutation were detected only in leukemic blasts at the onset of DCD TAM, but not in BM without the blasts before or after the onset of DCD TAM. These results suggest that the patient acquired trisomy 21 and a GATA1 mutation restricted to the leukemic clone derived from CB after birth. We hypothesized that immunosuppressive therapy to control GvHD after UCBT might have caused a defect in antitumoral immune surveillance for the elimination of malignant clones and that this influenced the onset of DCD TAM. Although the donor was phenotypically normal and healthy based on a medical check-up at birth and 6 months later according to the document from the CB bank, there is the possibility that the donor will develop TAM or subsequent ML-DS in the future. This raises ethical problems regarding whether the CB bank should inform the donor of this risk. However, the potential risk to the donor is supposedly quite limited because this is the first case of DCD TAM after UCBT from a phenotypically normal donor without DS. TAM patients often have liver disease complications, which are associated with hepatic infiltration with blast cells. 5 The patient developed hepatic veno-occlusive disease that resolved with supportive care. However, the presence of veno-occlusive disease was not biopsy-proven and had an unusual late-onset. This condition might have been a premonitory sign related to DCD TAM. The clinical and biological features of TAM seem to be almost identical regardless of whether a neonate has DS. 10 The patient should be followed up regularly to monitor the development of ML-DS for at least 5 years. In addition, recent studies showed that children with ML-DS have a favorable outcome with a cure rate of~80%, unlike in the case of AMKL without trisomy 21 and a GATA1 mutation. 15 If the patient develops ML-DS in the future, we need to consider these clinical features to plan the treatment strategy.
However, hematologists treating adult patients are not necessarily familiar with TAM, which develops only during childhood. In addition, even pediatricians might not recognize that TAM can occur in phenotypically normal and healthy neonates without DS. Therefore, hematologists managing UCBT might miss DCD TAM after UCBT or treat TAM without waiting for spontaneous remission. If blasts with morphological features of AMKL as DCD leukemia appear after UCBT, cytogenetic analysis of trisomy 21 and sequencing of GATA1 should be performed promptly to exclude DCD TAM after UCBT.
